CIAM
ABUS icon

Caitong International Asset Management’s Arbutus Biopharma ABUS Stock Holding History

Caitong International Asset Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.54K Buy
+1,363
New +$5.99K ﹤0.01% 1246
2026
Q1 		– Sell
-3,134
Closed -$15.1K – 2549
2025
Q4 		$15.1K Buy
+3,134
New +$14.1K ﹤0.01% 1054
2025
Q3 		– Sell
-784
Closed -$2.42K – 1879
2025
Q2 		$2.42K Sell
784
-39
-5% -$129 ﹤0.01% 1320
2025
Q1 		$2.87K Buy
+823
New +$2.75K ﹤0.01% 1210

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Caitong International Asset Management's ABUS Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Arbutus Biopharma (ABUS) in Q2 2026: 1,363 shares worth $6.54K. The stake represents ﹤0.01% of the portfolio and ranks #1246 among its holdings. This is a return to the name: Caitong International Asset Management previously reported a position in ABUS as recently as Q4 2025.

Caitong International Asset Management first reported a position in ABUS in Q1 2025 and has held it in 4 quarters since. The position peaked at $15.1K in Q4 2025. 176 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Caitong International Asset Management held 1,363 shares of Arbutus Biopharma worth $6.54K as of Q2 2026.
  • Arbutus Biopharma was a new Caitong International Asset Management position in Q2 2026.
  • Arbutus Biopharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1246 holding.
  • Caitong International Asset Management first reported a position in Arbutus Biopharma in Q1 2025 and has held it in 4 quarters since.
  • Caitong International Asset Management's Arbutus Biopharma position peaked at $15.1K in Q4 2025.
  • 176 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.